Treatment of AA Amyloidosis with an Underlying Neoplasm
When AA amyloidosis occurs in the setting of an underlying neoplasm, the tumour sustains a persistent inflammatory state that drives ongoing serum amyloid A production and progressive amyloid deposition. In this scenario, addressing the neoplasm directly is the cornerstone of management.
Clinical Scenario
This protocol applies to patients with confirmed AA amyloidosis in whom an underlying neoplasm has been identified as the source of chronic, high-grade inflammation. The neoplasm maintains the acute-phase response that fuels amyloid formation, making tumour control the primary clinical objective.
Treatment Approach
The protocol directs intervention at the underlying neoplasm itself — targeting the inflammatory driver rather than the amyloid deposits alone. The nature of the intervention depends on tumour type and clinical context.
The complete regimen — including all therapeutic options, selection criteria, and sequencing — is available in the full structured protocol below.
Clinical Goals
- Drastic reductions in serum acute phase reactant levels
- Reduction in amyloid deposits
References
DOI: 10.2147/CLEP.S39981
- Surgical excision of highly inflammatory neoplasm, such as localized Castleman's disease, has enabled drastic reductions in serum acute phase reactant levels and in amyloid deposits detected by scintigraphy in many cases.
View source ↗